Please ensure Javascript is enabled for purposes of website accessibility

Why Anavex Life Sciences Stock Soared 35% Today

By Eric Volkman - Jun 14, 2021 at 6:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Research published in a medical journal provides enormous hope for the company's pipeline Alzheimer's drug.

What happened

Shares of Anavex Life Sciences (AVXL 6.00%) got a serious boost on Monday. Two of the company's leading pipeline drugs were positively highlighted in peer-reviewed research that was newly published in a medical journal, and the shares rose to close the day over 35% higher.

So what

Late last week, the medical journal of Expert Opinion on Therapeutic Targets published research stating that two of Anavex's treatments for several afflictions related to the central nervous system, such as Alzheimer's, could be very effective in one aspect of fighting such diseases.

Elderly patient conferring with a doctor, as both men are face-masked.

Image source: Getty Images.

The authors wrote that the expression of one type of receptor (a protein that receives signals from the brain) that commonly increases in age, declines in patients suffering from Alzheimer's. As it decreases, so too does autophagy (which in the authors' words is "an intricate phenomenon that clears damaged cellular organelles and misfolded proteins").

One of the Anavex drugs specifically mentioned, ANAVEX2-73, has shown in clinical testing to induce autophagy. So, the researchers wrote, it's possible that treatments like it and the biotech's fellow CNS pipeline drug ANAVEX3-71 "could help the cells to compensate for the loss of other receptors and autophagy machinery."

Now what

ANAVEX2-73 has done well in clinical testing. In December, the company reported that a phase 2 trial showed that it relieved symptoms in adult female patients afflicted with the rare genetic disease Rett syndrome, and was proved safe. This latest research adds to the positive momentum of both that drug and ANAVEX3-71.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Anavex Life Sciences Corp. Stock Quote
Anavex Life Sciences Corp.
$11.65 (6.00%) $0.66

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.